Published on 26/11/2025

Model/Algorithm Validation: Conventional vs AI-Based AIS

Introduction to Automated Inspection Systems

The advent of Automated Inspection Systems (AIS) has drastically altered the landscape of quality assurance in pharmaceutical manufacturing. With technology evolving, there is a paradigm shift from traditional manual inspection methodologies to sophisticated AI-based algorithms that enhance operational efficiency and accuracy. This article will explore the validation processes associated with conventional and AI-based AIS, focusing on key regulatory requirements and best practices under US FDA, EMA, and MHRA expectations.

Visual inspection plays a crucial role in ensuring product quality and compliance with regulatory standards. It involves examining products (often parenterals and biologics) for defects, ensuring that each unit meets the established specifications. Validation of these inspection systems is not merely a regulatory requirement but a necessity to maintain product integrity and patient safety.

Understanding the Validation Lifecycle

Validation is a critical component of quality management systems (QMS) within the pharmaceutical industry. It is important to approach validation in a structured manner that includes various stages, all of which adhere to the principles outlined in guidance documents such as 21 CFR Part 11 and the EMA guidelines. The validation lifecycle typically consists of the following stages:

• User Requirement Specification (URS): The foundation for validation lies in defining clear user requirements. URS should encapsulate all intended uses, performance criteria, and regulatory expectations.
• Installation Qualification (IQ): This process verifies that the AIS is installed correctly according to manufacturer’s specifications and meets the initial user requirements outlined in the URS.
• Operational Qualification (OQ): During OQ, an evaluation is performed to determine if the AIS operates according to the established protocols in a controlled environment.
• Performance Qualification (PQ): The final phase assesses whether the AIS consistently performs its intended functions under real-world manufacturing conditions.

In the context of AI-based systems, unique considerations arise due to elements inherent in machine learning (ML). Validation must encompass not only initial performance metrics but also ongoing evaluation to accommodate system learning and adaptations over time.

User Requirements Specification (URS) for AIS

The URS is a critical document that encapsulates the expectations and requirements for an AIS. It should clearly detail the different attributes that the system must meet to ensure effective inspection. Some essential components of a URS for AIS include:

• Inspection Parameters: This includes specifics such as defect types, sizes, and acceptable quantifiable metrics for defect detection rates.
• Regulatory Compliance Needs: Documentation must align with applicable guidelines, such as those outlined in Annex 1 of the EU GMP guidelines.
• Integration with Existing Systems: The URS should define how the AIS will integrate with current manufacturing systems and IT infrastructure, including data management and compliance tracking.
• Traceability and Reporting: Requirements regarding data retention, analysis, and reporting frequency should be specified to ensure audit readiness.

The URS serves as the baseline for the validation of automation systems and AI models, ensuring that all functional aspects are addressed before development and deployment.

Installation Qualification (IQ) in Validation

The IQ phase is designed to confirm the proper installation of the AI-based Automated Inspection System. This part of the validation process includes several key activities:

• Documentation Review: Verification that all relevant installation documentation provided by the vendor, including equipment manuals, installation protocols, and specifications, is available and complete.
• Component Verification: Each component of the AIS must be inspected and confirmed to be the correct model/version, as per the specifications outlined in the URS.
• Environmental Conditions: Assessment of whether the environmental conditions (temperature, humidity, etc.) where the AIS will operate meet required specifications.
• System Configuration Checks: Ensure that the AIS configuration adheres to predefined settings optimized for defect detection and visual interpretation.

Documenting the IQ phase is essential, as it provides a foundation for further qualifications (OQ and PQ) and demonstrates a commitment to compliance with validation protocols.

Operational Qualification (OQ) Details

Operational Qualification (OQ) is performed after the IQ phase and is integral to confirming that the AIS operates as intended. OQ involves rigorous testing of the system’s functionalities to confirm that all aspects meet performance criteria established in the URS.

For AI-based AIS, OQ needs to incorporate unique elements:

• Functional Testing: This is the process of verifying that each function operates correctly over a defined range of operating conditions. For example, the AI should accurately identify defects within a specified threshold of operational parameters.
• Algorithm Performance Testing: Specialized tests tailored to the AI algorithm must be conducted to ensure the system’s learning is aligned with expected outcomes. This may involve analyzing predictions against a defect library.
• Challenge Set Testing: The use of challenge sets, which are specifically designed defect examples, will help assess the system’s robustness and accuracy, reducing the false reject rate.
• Documentation and Reporting: All OQ test results must be documented meticulously to maintain compliance and provide a basis for PQ evaluation.

The success of this stage not only builds confidence in the system’s operational capabilities but also contributes to regulatory compliance through documentation and performance metrics.

Performance Qualification (PQ) Strategies

The final phase of the validation lifecycle, Performance Qualification (PQ), assesses whether the AIS functions as intended in real-world production settings. Proper execution of PQ is paramount for ensuring ongoing compliance and operational efficiency.

This phase focuses on:

• Real-World Testing: Conduct tests using real production batches to validate that the AIS can consistently identify defects across multiple runs, ensuring variability does not compromise performance.
• Longitudinal Study of Inspection Results: Implement a statistical approach to analyze inspection results over time. This should include trending data aligned with quality performance indicators (KPIs) related to defect detection.
• Calibration Exercises: Regular calibration ensures the AIS maintains its operational integrity and meets regulatory expectations outlined in Annex 15 which relates to qualification and validation specificities.
• Ongoing Monitoring: Establish a framework for ongoing evaluations and routine checks to ensure quality control and adjust settings as needed to maintain high performance. This aspect is key in addressing and reducing the false reject rate.

The PQ phase provides assurance not only of product quality but also enhances trust in the regulatory compliance of the manufacturing process.

AI-Based vs. Traditional Approach to Validation

This segment will explore the challenges and strategies related to both AI-based and traditional AIS validation approaches. Traditional methods typically involve human oversight with set static rules for inspection, whereas AI requires continuous feeding of data and learning algorithms.

• Static vs. Dynamic Environments: In traditional systems, once validated, the settings remain fixed. In contrast, AI systems evolve, necessitating regular recalibration against established challenge sets and performance criteria, especially those concerning the defect library.
• Data Management: With AI systems, considerable emphasis is placed on data integrity and management. Validation must ensure that data pipelines are compliant with standards such as those outlined in 21 CFR Part 11.
• Regulatory Challenges: AI systems introduce complexities in validation that go beyond traditional models, emphasizing the need for clarity in regulatory frameworks that address machine learning in pharmaceutical inspections.
• Integration of Human Oversight: While AI can reduce manual labor, human judgment remains critical. Validation processes must ensure that there is an adequate balance between machine decisions and human expertise to uphold product safety and compliance.

The convergence of AI and traditional inspection methodologies presents numerous opportunities, yet regulatory bodies have begun to emphasize exhaustive validation processes to safeguard quality across both paradigms.

Regulatory Considerations for Validation

In the realm of pharmaceutical validation, adherence to regulatory standards is non-negotiable. Regulatory organizations such as the FDA, EMA, and MHRA provide foundational frameworks that guide validations of Automated Inspection Systems. Key considerations include:

• Documentation Standards: Maintain comprehensive documentation aligned with guildelines such as those presented in the EMA’s guidance on stability testing, which asserts the importance of robust documentation processes.
• Data Integrity Principles: Regulatory bodies expect rigorous applications of data integrity principles, governing how data is recorded, stored, and analyzed within Automated Inspection Systems.
• Adaptation to Changing Guidelines: As regulatory frameworks evolve, the validation processes for AIS must adapt accordingly to maintain compliance; ongoing training and updates on regulatory changes are vital to ensuring compliance.
• Inspections and Audits: Preparedness for inspections requires having comprehensive validation documentation and training records accessible to demonstrate the effectiveness of the validation lifecycle.

It is essential that validation efforts maintain not only compliance but also build a foundation for trust between stakeholders, encompassing patients, manufacturers, and regulatory agencies.

Conclusion

In conclusion, the validation of Automated Inspection Systems, whether conventional or AI-based, is multifaceted and requires an in-depth understanding of the entire process from URS to PQ. The shift from traditional methods to AI mandates a recalibration of approaches, emphasizing the need for structured validation processes that prioritize product quality and regulatory compliance.

By establishing a rigorous validation framework, pharmaceutical professionals can ensure that their AIS integrates the best aspects of technology and human oversight to achieve optimal performance. This alignment not only meets regulatory expectations but also advances overall operational excellence within the industry.